Lidomex

Quick links to important sections

Lidomex

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lidomex

Quick Facts: At a Glance

Property Description
Active Ingredient Prednisolone Valeroacetate (Prednival)
Brand Origin/Manufacturer Kowa Company, Japan (e.g., LIDOMEX KOWA)
Form Cream and Ointment (Topical)
Pharmacological Class Glucocorticoid, Corticosteroid
Origin Synthetic Compound

What Is Lidomex and Its Pharmacological Classification?

Lidomex is a branded, synthetic compound specifically classified as a topical glucocorticosteroid preparation, which is obtainable only with a prescription. The core active ingredient is Prednisolone Valeroacetate, an ester of the glucocorticoid Prednisolone that is structurally modified to enhance its action. This compound is formally categorized within the major Pharmacological class of Corticosteroids and Glucocorticoids. The specific Lidomex brand is commonly associated with approvals in jurisdictions such as Japan, establishing its particular manufacturing provenance by Kowa Company.

Composition and Available Drug Forms

The formulation utilizes the single active ingredient Prednisolone Valeroacetate, which is mixed into an Emollient Base vehicle for Topical (Dermal/Cutaneous) administration. The product is supplied in two primary Dosage form(s): a cream and an ointment. The valeroacetate derivative is designed to provide effective anti-inflammatory activity on the skin. The availability of both cream and ointment forms allows for therapeutic flexibility, depending on whether a lighter or more occlusive application is required for the skin condition.

General Purpose: Anti-inflammatory Action and Relief

The overarching General purpose of this preparation is to provide powerful, localized relief from inflammatory and allergic skin conditions. By functioning as a potent Anti-inflammatory agent and localized Immunosuppressant agent, it is clinically used for conditions that present with significant redness, swelling, and irritation. The drug helps to stabilize the skin’s overactive response, which subsequently manages the persistent discomfort and itching associated with these inflammatory issues.

Regulatory References

  1. GSRS Substance: PREDNISOLONE VALERATE ACETATE

What side effects are possible with Lidomex?

Possible Side Effects and Safety Information

Lidomex (prednisolone valerate acetate) is a synthetic adrenal corticosteroid. Its safety profile, based on regulatory documentation, is characterized by potential localized skin reactions and, rarely, more serious ocular complications.


Adverse Reactions

The most commonly reported adverse reactions are generally localized to the application site. Rare, but serious, effects are also officially documented.

Classification Common Reactions Rare/Serious Reactions
Skin & Local Stimulating feeling, folliculitis, itch, worsening of rash, trichophytosis, erythema.
Ocular System Intraocular hypertension, glaucoma, cataract.

Serious reactions such as intraocular hypertension, glaucoma, and cataract are considered rare but necessitate immediate consultation with a healthcare professional if symptoms like eye pain, light sensitivity, blurred vision, or headache occur.


Safety Considerations and Restrictions

Contraindications

Lidomex is strictly contraindicated in the presence of various skin infections (bacterial, fungal, viral, etc.), skin diseases caused by insects, or if the patient has eczematous external otitis with eardrum perforation, ulcers, heat burns, or frostbite. Use is also restricted for individuals with a known history of allergic reactions to the medicine.

Population-Specific Caution

Special care and professional guidance are required when this medicine is used by individuals who are pregnant or breastfeeding. Furthermore, when applying the medicine to the diaper area of an infant, the instructions of a doctor or pharmacist must be strictly followed.

Application Limitations

Lidomex is for external use only. It must not be applied into the eyes, nor should it be used as a makeup base or after-shave product. Patients must not discontinue the use of this medicine without the instruction of their prescribing physician.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on documented findings and regulatory guidance regarding overexposure to topical corticosteroids.

Overdose Manifestations and Risks

Overdose Context Regulatory Statement
Acute Overexposure Acute overdosage with this topical formulation is not ordinarily expected to cause acute problems.
Chronic Overdose Risks The primary concern is the potential for systemic effects from prolonged, high-dose use, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations resembling Cushing's syndrome.
Antidote No specific antidote is known for corticosteroid overdosage.

Required Emergency Actions

Seek immediate medical attention for any suspected overdose or accidental ingestion, as mandated by regulatory authorities. Contact a Poison Control Center or emergency services immediately if the cream or ointment is ingested or if signs of systemic toxicity are observed after long-term use. Supportive treatment is the documented management approach. If the product is accidentally ingested, the required supportive measure is to drink fluids to dilute the concentration.

Therapeutic Uses of Lidomex

What Lidomex Treats: Main Uses and Benefits

The active ingredient, Prednisolone Valeroacetate, is used to provide support for symptomatic relief across domains involving inflammatory or irritative states. In therapeutic areas involving inflammatory and pruritic presentations of dermatologic disorders, this class of medication is considered relevant for easing symptoms.

The product is commonly used across conditions presenting with acute episodes, which may include Eczema/Dermatitis Syndrome, Psoriasis, Prurigo Syndrome, and Palmoplanter Pustulosis. It is applied across domains where additional symptomatic support is needed, such as when symptoms become more noticeable or challenging.

The primary benefit is its role in managing symptom clusters related to inflammatory states, such as symptoms related to physical discomfort like redness (erythema) and swelling (edema), and itching (pruritus). This use contributes to improved day-to-day comfort during symptomatic periods, helping maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Symptoms Related to Inflammatory States

Property Description
Primary Indication Area Steroid-Responsive Dermatoses (e.g., Eczema, Psoriasis)
Symptom Focus Redness, Swelling, and Itching (Pruritus)
Clinical Context Management of acute flares and persistent, difficult-to-manage lesions
Patient Benefit Provides support that helps ease the overall symptom burden

Regulatory References

  1. NIH StatPearls in an overview of Topical Corticosteroids

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lidomex — official regulatory information

Eligibility scope

Classification Status
Populations for whom use is allowed (as stated in label) Adults are typically eligible for use under standard labeled conditions, provided no contraindications are present.
Populations for whom use is not recommended (if applicable) Use is generally restricted in the pediatric population, especially children under 12 years of age.
Populations for whom use is contraindicated Individuals with known hypersensitivity to any component of the formulation must not use this medicine.
Age-related eligibility rules Pediatric use is limited or not recommended due to an increased risk of systemic absorption and HPA axis suppression.
Condition-specific eligibility rules Contraindicated in patients with untreated primary viral, bacterial, or fungal infections of the skin in the treatment area.
Pregnancy and lactation eligibility status (if explicitly documented) Use during pregnancy or breastfeeding is typically classified as conditional or restricted, requiring regulatory justification.
Eligibility-related restrictions Use is strictly limited on the face, groin, or axillae and is contraindicated in patients with Rosacea or Perioral Dermatitis.

Eligibility classifications (high-level)

Classification Status
Eligibility severity classification (as defined in official documents) Contraindicated (absolute prohibition) for specific infections and local conditions.
Regulatory basis (EMA / FDA / etc.) Based on standard regulatory requirements for potent topical glucocorticoids.
Eligibility-context constraints (as defined in official documents) Restricted use over large surface areas or for prolonged periods due to systemic absorption risk.

Resulting eligibility structure

Official eligibility statements:

  • The medicine is strictly contraindicated in the presence of certain local dermatoses, including rosacea and perioral dermatitis.
  • Use is not recommended in younger children due to a higher susceptibility to systemic effects.
  • Eligibility is denied for patients with primary infections of the skin or a documented allergy to the active ingredient.

Connection to the overall eligibility profile: The regulatory profile formally defines who can and cannot use the medicine by listing specific local infections, hypersensitivity, and specific skin disorders as absolute exclusions. Furthermore, it restricts use based on age and physiological states to mitigate systemic exposure risks, ensuring the medicine is confined to its labeled population and context.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Lidomex (prednisolone valerate acetate topical) emphasize that, due to its topical route of administration, the risk of clinically significant drug-drug interactions is generally considered minimal. Consequently, the regulatory profile does not list any specific interacting medicinal products, food, or alcohol that are contraindicated or require special separation in time.

Interaction-Related Procedural Constraints

No specific interaction warnings are issued for this medication; the primary instruction is procedural and cautionary in nature.

Classification Official Statement/Constraint
Specific Interacting Medicines None explicitly listed in official labeling.
Contraindicated Combinations None explicitly documented.
Interaction Requirement Inform your doctor or pharmacist of all other medicinal products (including over-the-counter medicines and dietary supplements) being taken.

Interaction Profile Summary

The official labeling does not specify any interactions related to metabolic pathways (like CYP enzymes) or drug transporters (like P-gp) because the amount of active ingredient absorbed systemically is typically negligible. The overall structure of the interaction profile reflects the low systemic exposure, leading to the absence of concrete restrictions on co-administration with other specific medications, food, or supplements.

Mechanism of Action

The Mechanism of Action for Lidomex is detailed across three key domains. The primary mechanism involves Lidomex acting as an inhibitor of voltage-gated sodium channels ( Na v) found on the membranes of nerve cells. The compound binds from the intracellular side when the channel is in its inactive state (use-dependent block), preventing the rapid influx of Na^+ ions. This blockade halts the attainment of the depolarization threshold, causing the cessation of afferent electrical signaling along the sensory nerve axon.

When systemically present, the drug affects the cardiac conduction system by modulating the Na v1.5 subtype of sodium channels in ventricular tissue. This modification alters the kinetics of the action potential, resulting in a change in the effective refractory period and conduction velocity and leading to the alteration of cardiac electrical activity.

A secondary mechanism involves the suppression of immune signaling cascades, such as the NF-kappa B pathway, in immune and glial cells. This interference results in the down-regulation of the biosynthesis and release of pro-inflammatory mediators, contributing to a localized reduction in cellular immune activation (149 words).

Dosage and Administration Information

How Lidomex Is Used

Lidomex, containing Prednisolone Valeroacetate, is strictly designated for topical administration, meaning it is applied directly to the skin's surface. This glucocorticoid preparation is typically supplied in formulations of cream, ointment, or lotion at a strength of 0.3%. The official instructions for its use define the high-level principles for proper application, timing, and specific procedural constraints.

Administration and Dosage Regimen

Application involves applying an appropriate amount of the preparation to the specific affected area of the skin. This dosage is not fixed numerically but is adjusted by a professional according to the patient’s symptoms and disease condition, reflecting a needs-based administration pattern.

  • Frequency: Application is typically specified as once to several times a day.
  • Duration: The product should not be stopped abruptly without the instruction of a doctor, as treatment duration is flexible and determined by clinical needs.

Procedural Rules and Constraints

Specific rules exist to ensure correct application according to regulatory guidelines. For the lotion form, the product must be shaken well before applying.

Administration is subject to key procedural constraints: The product must not be applied to the eyes, and its use is prohibited as a cosmetic base, such as a makeup base or aftershave. For infants and children, application to the diaper area requires close attention and specific medical instruction due to potential for increased absorption.

Handling of Missed Timing

If an application is missed, it should be applied as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients are explicitly instructed not to use two doses at one time to compensate for a missed application, preserving the integrity of the treatment schedule.

Recent Clinical Evidence

Research Evidence Overview of Topical Prednisolone Valeroacetate

Evidence from Trials in Atopic Eczema and Dermatitis Syndrome

The research record contains short-term Randomized Controlled Trials (RCTs) exploring the use of potent topical corticosteroids in the context of atopic eczema and dermatitis. These studies compared the preparation to an inactive cream or other similar treatments. Researchers examined outcomes linked to inflammatory states, such as the reduction of redness and swelling, and also monitored patient-reported outcomes describing perceived discomfort, particularly itching.

Research reports described measurements of change in disease severity scores and monitored symptom status in the observed populations during the acute treatment period, which typically lasted less than six weeks.

Evidence from Studies in Psoriasis

The use of topical Prednisolone Valeroacetate was evaluated in studies focusing on localized plaque psoriasis. Research examined changes in specific physical outcomes related to the lesions, such as measurements of thickness and scaling, using standardized physician assessments. These studies were generally short-term, often comparing the topical preparation against other similar agents.

Long-Term Research and Follow-up Duration

Controlled research for this medication class has primarily focused on acute periods and short-term symptom patterns. Therefore, follow-up durations were limited, often restricted to the initial few weeks of treatment. Longer-term data often come from observational settings rather than large, controlled trials. This means that the long-term effects are not fully established, and evidence is limited regarding the durability of findings after treatment is stopped or when the medication is used intermittently for maintenance.

Scientific Gaps and Areas of Uncertainty

The research landscape is marked by several limitations. Sample sizes were modest in many specific trials for the active ingredient, and data for certain groups, such as those with significant comorbidities or specific lesion subtypes, remain insufficient. While research describes how short-term symptoms are measured and monitored, the overall evidence quality varies across studies, particularly for the less common indications. The evidence highlights what is known—and what is still uncertain—about long-term use and specific patient outcomes.

Key Studies & References

  1. Topical Corticosteroids - StatPearls - NCBI Bookshelf
  2. Psoriasis clinical guideline - American Academy of Dermatology
  3. Label: PREDNISOLONE ACETATE suspension/ drops - DailyMed - NIH (Regulatory/Active Ingredient Context)

Frequently Asked Questions (FAQ)

Common questions about Lidomex (FAQ)

Q: Are there any common foods or drinks that should be avoided while taking Lidomex?

A: Official labeling for this topical medicine does not explicitly list any foods or drinks that must be avoided. This is because the medicine is applied to the skin, and only a very minimal amount is typically absorbed into the body when used as directed. Therefore, specific dietary restrictions are generally not included in the official product information.


Q: Do studies suggest Lidomex is a long-term treatment option?

A: Official documents often limit the use of this potent topical medicine to short durations. Prolonged use or application over large body areas is associated with an increased potential for systemic effects, such as the suppression of the body’s natural steroid production (HPA axis suppression). Regulatory documents indicate that use exceeding short periods requires ongoing professional evaluation.


Q: Is there a generic version of Lidomex available?

A: Lidomex is the specific brand name for the active ingredient prednisolone valeroacetate. While the active ingredient itself may be available in other products, the existence and availability of an exact generic equivalent often depend on the specific country's regulatory approvals and market status for that ingredient.


Q: Can a person stop taking Lidomex suddenly, or does it need to be done gradually?

A: According to official instructions, the use of this medicine must not be stopped abruptly. Treatment duration is defined by professional guidance based on the patient's specific condition. It is important that any decision to stop or change the application frequency is made only under professional instruction.


Q: Does the time of day I take Lidomex matter?

A: Regulatory documents state that application can be specified as once to several times a day, depending on the professional's instructions. There is no official constraint in the labeling specifying the time of day (e.g., morning versus evening) that the medicine must be used.


Q: Can Lidomex be crushed or split if a person has trouble swallowing pills?

A: Lidomex is manufactured only for topical use and is supplied as a cream, ointment, or lotion. It is not an oral pill or tablet intended to be swallowed. Therefore, the question about crushing or splitting oral forms does not apply to this skin medicine.


Q: Can Lidomex be taken at the same time as vitamin or mineral supplements?

A: Due to its topical route of administration and minimal systemic absorption, the regulatory profile does not list any specific vitamin or mineral supplements that are contraindicated or require special separation in time from this medicine.


Q: Is Lidomex the kind of drug that can cause dizziness or affect driving?

A: The most common reported adverse reactions are localized skin reactions at the application site. Systemic effects such as dizziness or changes that might affect driving are not commonly listed for this topical formulation, reflecting the minimal amount of medicine absorbed into the body when used as directed.


Q: Are there rules about having alcohol while taking Lidomex?

A: Official labeling for this topical medicine does not list alcohol as an interacting product that is contraindicated or requires special avoidance. This is consistent with the minimal amount of the medicine absorbed into the body when it is applied to the skin.


Q: How long does Lidomex typically stay in the body after the last dose?

A: Due to its design for topical application, the amount of the active ingredient that is absorbed systemically is generally negligible. This means the medicine does not typically remain at detectable levels in the bloodstream for a prolonged period, unlike some oral medicines.


Q: Can people with liver problems use Lidomex, based on official descriptions?

A: Official contraindications focus on local skin conditions and infections at the application site. Systemic conditions like liver problems are not listed as primary contraindications due to the medicine's topical administration and minimal expected systemic absorption.


Q: Does Lidomex interact with herbal supplements like St. John's Wort?

A: Official documents do not list specific herbal supplements, including St. John's Wort, as being known to interact with this topical medication. The risk of such interactions is considered minimal due to the medicine's low systemic absorption.


Q: Can taking Lidomex cause changes in weight?

A: Systemic side effects such as weight changes are associated with prolonged use, high doses, or application over a very large body surface area, which can increase systemic absorption. These effects are generally not reported when the medicine is used according to its labeled topical instructions.


Q: Does Lidomex affect a person's immune system?

A: As a glucocorticoid, one of the primary actions is the localized suppression of inflammatory and immune signaling cascades in the skin. The potential for systemic immune effects increases if the medicine is absorbed in significant amounts, which is a consideration with extensive or prolonged use.


Q: Are there different brand names for the same medicine as Lidomex?

A: Yes, the active ingredient prednisolone valeroacetate is an established compound. It is marketed under different brand names in various countries by different manufacturers, depending on local regulatory approvals.


Q: Do people generally need to change their diet while on Lidomex?

A: No specific changes to a person's general diet are generally required or advised in the official documentation for this topical medicine.


Q: Does Lidomex have a risk of dependence or withdrawal?

A: The potential risk is related to systemic absorption with prolonged or extensive use, which can include the possibility of HPA axis suppression. If systemic absorption is a concern, cessation may require professional guidance to avoid potential adverse outcomes related to systemic effects.


Q: Is it normal for the color of the pill to be slightly different sometimes?

A: Lidomex is formulated as a topical cream, ointment, or lotion, and not as an oral pill or tablet. Therefore, questions regarding the color variation of a swallowed form do not apply to this medicine.


Q: What kind of routine blood tests might be associated with taking Lidomex?

A: While routine blood tests are not always stated as necessary for typical topical use, monitoring for systemic effects, such as HPA axis suppression or changes in metabolic parameters, may be indicated for prolonged or extensive use.


Q: Is it common to feel tired when first starting Lidomex?

A: Tiredness or fatigue is not typically listed as a common local side effect in the official documents. This type of systemic feeling is only likely to be noticed if the medicine is absorbed in larger than intended amounts, which is rare when used as directed.


Q: Does Lidomex affect sleep patterns for most people?

A: Changes to sleep patterns are not commonly reported with this topical medicine. If significant systemic absorption occurs (such as with high doses or prolonged use), some individuals may experience effects on sleep, as is sometimes seen with oral corticosteroids.


Q: Does Lidomex interact with common pain relievers like ibuprofen?

A: The official documentation does not list specific interactions with common pain relievers such as ibuprofen. This reflects the medicine's topical route and minimal systemic absorption, which lowers the overall risk of drug-drug interactions.


Q: Are there any specific lifestyle changes that are often suggested with Lidomex use?

A: Official documents define specific procedural rules for use, such as proper application techniques, avoiding the eyes, and not using it as a cosmetic. No broad, non-procedural lifestyle changes are typically suggested in the medicine's labeling.


Q: What regulatory bodies have approved Lidomex for use?

A: The Lidomex brand is primarily associated with regulatory approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The active ingredient, prednisolone valeroacetate, is approved for use in various markets globally by their respective regulatory bodies.

How should Lidomex be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions necessary to maintain the quality and stability of Lidomex (e.g., Cream 0.3% or Lotion 0.3%).

Storage and Protection Requirement Details
Environmental Protection Store away from direct sunlight, heat, and moisture to ensure product stability.
Child Protection The medicine must be kept out of the reach of children.
Post-Use Stability Discard the remainder of the product after use. The regulatory document explicitly states not to store any remaining portion.

These official statements define how the medicine must be protected from environmental factors and include mandatory instructions for disposal. The requirement to discard any remainder immediately after use sets a clear constraint on the product's in-use stability.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lidomex found in:

A-Z Index: